Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
The Drug-drug Interaction of SP2086 and Simvastatin
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02815722
- Locations
- 🇨🇳
People's Liberation Army General Hospital of Chengdu Military Region, Chengdu, China
The Drug-drug Interaction of SP2086 and Metformin
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02813863
A PhaseⅡ/ Ⅲ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 348
- Registration Number
- NCT02811991
- Locations
- 🇨🇳
Fuzhou General Hospital of Nanjing Millitary Command, Fuzhou, Fujian, China
🇨🇳Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
🇨🇳No.1 People's Hospital of Chenzhou City, Chenzhou, Hunan, China
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02766140
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02764268
- Locations
- 🇨🇳
Shanghai 6th People's Hospital, Shanghai, Shanghai, China
A Phase 1, Randomized, Placebo-controlled, Single & Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Healthy Chinese Volunteers
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT02750553
A PHASE I, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SHR0534 IN HEALTHY VOLUNTEERS
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02749097
A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT02742935
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02738489
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Beijing University, Beijing, Beijing, China
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT02721589
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Zhongshan University, Guangzhou, Guangdong, China
© Copyright 2024. All Rights Reserved by MedPath